SEHK:1801Biotechs
Innovent Biologics (SEHK:1801) Partners With Fangzhou For AI-Driven Diabetes Care In China
Innovent Biologics (SEHK:1801) has recently been part of a significant client announcement, with a new partnership with Fangzhou Inc. aimed at integrating digital health services into innovative therapies for metabolic diseases. This event coincided with the company's share price rising 23% over the last quarter. Aside from this strategic move, the company has also witnessed FDA approval for key investigational drugs such as IBI363, adding weight to its impressive price performance. However,...
